
Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).

Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).

“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.

"Same-day discharge is safe and feasible across a broad spectrum of FPMRS cases," says Jacqueline Zillioux, MD.

In this video, 5 urologists each weigh in on whether they listen to music in the OR, and if so, what they like to listen to.

Terrence Regan, MD, also discusses appropriate use criteria for advanced imaging from the Centers for Medicare & Medicaid Services.

“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.

“[Prior authorization is] becoming a bigger and bigger problem for each practice,” says urologist Terrence Regan, MD.

“[Prior authorization has] become part of our everyday practicing life, but it does very little to advance quality of care,” says Terrence Regan, MD.

“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.

“The side that can take…complex issues and make them simple…is likely going to be the side that wins in a case,” says Kenton H. Steele, Esq.

Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.

Urologists Steven M. Wahle, MD, and Henry Rosevear, MD, catch up with each other in this wide-ranging conversation.

“If we allow a cardiologist to be critical of a family medicine practitioner, there's a chance that they're being held to an unreasonable standard that doesn't apply to their day to day, which is why that requirement is in place for most but not all states,” says Kenton H. Steele Esq.

"I do think there's a big opportunity, if [telemedicine is] used correctly, to overcome some of these workforce shortages," says Chad Ellimoottil, MD, MS.

“We found that medications allegedly causing priapism and the litigation surrounding that is significant because it means that the patient-physician relationship was not well established,” says Ariana Matz, MD.

In this interview, Amy M. Pearlman, MD, also discusses how she uses social media at professional conferences.

“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.

Urologist Amy M. Pearlman, MD, discusses how she uses social platforms such as Twitter, Facebook, and Tiktok to entertain and inform.

“It's important for any urologist to gain a broader exposure and awareness to the tools and techniques available to help improve efficiency in the operating room and reduce the amount of wasteful time in between cases,” says Niki N. Parikh, MD, MBA, MSBA.

Laura Bukavina, MD, MPH, and Justin Dubin, MD, also discuss their own usage of social media and share advice for medical professionals using social media.

“We had a very low rate of nonattendance amongst oncology appointments, as compared to some other appointments,” says Randie White, MD.

“There is a lot of debate about the final shape and form of what telemedicine should look like,” says Chad Ellimoottil, MD, MS, in this video.

In this video, Jennifer M. Taylor, MD, MPH, also shares one of her strategies to cope with burnout and provides advice for others struggling with burnout.

“We found that there is going to be a significant proportion of growth in the urology work force related to the number of women in urology, which is really exciting,” says Kate H. Kraft, MD.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for prostate cancer and other PARP agents are moving through the pipeline.

Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.

“Speak out. speak out. If you're a physician who's going through a hard time, I can promise you you're not alone,” says Raj S. Pruthi, MD, MHA, FACS.

“I really fell in love with [urology] from the get go,” Kraft says.

“In this study, we show that AI can be used to speed up the time-consuming step of outlining the prostate that's required for targeted prostate biopsy,” says Geoffrey Sonn, MD.

“In my opinion, burnout has nothing to do with weakness or laziness or incompetence,” says Raj S. Pruthi, MD, MHA, FACS.